Onco Wiki / Indication

Kaposi sarcoma · line 1 · Pegylated liposomal doxorubicin monotherapy (Kaposi sarcoma)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Ligne thérapeutique1
Voiestandard
Régime liéREG-PLD-KAPOSI
IDIND-KAPOSI-1L-VISCERAL-PLD
TypeIndication
Étatreviewed 2026-07-11 | pending_clinical_signoff
MaladiesDIS-KAPOSI
SourcesSRC-NCCN-SKIN-2025 SRC-NIH-AIDS-2024

Notes

STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation), covering visceral/extensive disease of ANY epidemiologic form. Introduces new Regimen REG-PLD-KAPOSI (reuses the existing DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN entity; dosing transcribed from that entity's pre-existing typical_dosing field, not newly invented -- verified by direct read during independent review). `concurrent_therapy` is deliberately left empty rather than hard-coding REG-HIV-BIKTARVY or REG-SIROLIMUS-KAPOSI-CONVERSION, because this Indication spans ALL epidemiologic forms and only a subset needs concurrent form-specific immune-restoration therapy -- see `rationale` for the form-specific guidance instead. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not Kaposi sarcoma chemotherapy -- downgraded to "context". SRC-NIH-AIDS-2024 kept as "context" (not "supports") because it substantiates the concurrent-ART-continuation guidance but not the PLD dosing/chemotherapy content itself, which is drawn from the DRUG enti...

Utilisé par

Algorithmes

Maladie

Indication